Newswise — People with end-stage renal disease often undergo hemodialysis, a life-sustaining blood-filtering treatment. To make the process as fast and efficient as possible, many people have “hemodialysis grafts” surgically implanted. These grafts are like bypasses, connecting a vein to a major artery, making it easier to access blood and ensuring the same blood doesn’t get filtered twice.
But the grafts have a notorious problem: Clots tend to form where the graft is attached to the vein. For the person undergoing dialysis, this means not only a break from treatment, but also surgery to remove the graft and then surgery to implant another.
A multidisciplinary team from Washington University School of Medicine in St. Louis and the university’s McKelvey School of Engineering have devised a new way to design grafts that decreases the risk of clotting, ultimately relieving people of the pain, inconvenience and disruption of this critical treatment.
The research was published June 10 in the journal Scientific Reports.
In the United States, more than 500,000 people have end-stage renal disease.
“This has been a persistent problem for my patients, and we knew there had to be a better way,” said Mohamed Zayed, MD, PhD, associate professor of surgery and of radiology in the section of vascular surgery and senior author of the study. “There is only so much blood thinner a patient can tolerate to prevent graft clotting, so we turned from pharmaceutical solutions to mechanobiology.”
The field of mechanobiology considers all of the physical properties of a biological system, not simply the chemistry. How do the mechanical forces at play — for example, pressure, elasticity, tension — shape the formation of blood clots?
The team involved in this research got together via the Center for Innovation in Neuroscience and Technology (CINT) at the School of Medicine.
“Washington University is one of the only places where conversations like this happen regularly and purposefully between physicians and engineers,” said Guy Genin, the Faught Professor of Mechanical Engineering at the McKelvey School of Engineering and a joint senior author on the paper.
“CINT has been driving conversations like this for years and serves as a powerful platform for translating cutting edge science to the clinic. Through CINT, Mohamed Zayed was able to identify an application for research results from the National Science Foundation Science and Technology Center for Engineering Mechanobiology, and we were all able to turn it into a product that can directly benefit patients.”
Genin serves as co-director of the NSF Center and as CINT’s chief engineer.
To figure it out, the researchers worked under the domain of the Center for Innovation in Neuroscience and Technology (CINT), a cross-disciplinary group working to remove classic barriers between engineering and medicine to allow a more fluid exchange of ideas and insights.
While a master’s student at McKelvey, lead author Dillon Williams, now a doctoral student at the University of Minnesota, wrote his thesis on the redesign of dialysis grafts. “Dillon’s key insight was that features of the surgery that the surgeon typically does not control can be tailored to reduce the chances that cells in the blood receive the mechanobiological cues that lead them to form clots,” said Guy Genin, the Faught Professor of Mechanical Engineering at Washington University and joint senior author on the paper.
The surgeon doesn’t have to simply build a bypass, but they can also act as a kind of civil engineer, paying attention to a specific design element in order to reduce the likelihood of a buildup of blood cells.
The team’s research revealed that the crucial design element was the angle at which the graft and the vein were connected. It could be tailored so as to reduce both high and low rates of shear strain in the blood, a force that warps blood vessel walls in a specific way.
“These can be nearly eliminated by judicious choice of the attachment angle,” Zayed said. “Although it is not always possible to reach the optimal range of attachment angles that Dillon discovered, the results tell us how to design prosthetic grafts that stand to reduce thrombosis [clot formation] substantially.”
The work has been submitted as a non-provisional patent application — Williams’ second as a McKelvey student — and the team hopes to bring it to the clinic soon. “CINT has a strong track record of bringing new technologies all the way to the clinic,” said Eric Leuthardt, MD, professor of neurosurgery and director of CINT, and an author on the study. “Washington University is a place where we can bring together the right ideas and the right people, including outstanding McKelvey students like Dillon.”
The McKelvey School of Engineering at Washington University in St. Louis promotes independent inquiry and education with an emphasis on scientific excellence, innovation and collaboration without boundaries. McKelvey Engineering has top-ranked research and graduate programs across departments, particularly in biomedical engineering, environmental engineering and computing, and has one of the most selective undergraduate programs in the country. With 140 full-time faculty, 1,387 undergraduate students, 1,448 graduate students and 21,000 living alumni, we are working to solve some of society’s greatest challenges; to prepare students to become leaders and innovate throughout their careers; and to be a catalyst of economic development for the St. Louis region and beyond.
This work was supported by the Washington University in St. Louis Skandalaris Center Leadership and Entrepreneurship Acceleration Program (M. Zayed); the Society for Vascular Surgery Foundation (M. Zayed); the American Surgical Association Foundation (M. Zayed); the National Institutes of Health National Heart, Lung, and Blood Institute, No. R41HL150963 (M. Zayed); the Center for Innovation in Neuroscience and Technology at Washington University in St. Louis (E. Leuthardt); and the National Science Foundation Science and Technology Center for Engineering MechanoBiology, No. CMMI 1548571 (G. Genin)